Open AccessAnti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
Author(s) -
Alice L. Yu,
Andrew L. Gilman,
M. Fevzi Özkaynak,
Wendy B. London,
Susan G. Kreissman,
Helen X. Chen,
Malcolm A. Smith,
Barry Anderson,
Judith G. Villablanca,
Katherine K. Matthay,
Hiro Shimada,
Stephan A. Grupp,
Robert C. Seeger,
C. Patrick Reynolds,
Allen Buxton,
Ralph A. Reisfeld,
S. D. Gillies,
Susan L. Cohn,
John M. Maris,
Paul M. Sondel
Publication year - 2010
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa0911123
Subject(s) - medicine , isotretinoin , immunotherapy , neuroblastoma , oncology , concomitant , gastroenterology , immunology , surgery , cancer , dermatology , biology , acne , genetics , cell culture
Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity against neuroblastoma and that such activity is enhanced when ch14.18 is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-2. We conducted a study to determine whether adding ch14.18, GM-CSF, and interleukin-2 to standard isotretinoin therapy after intensive multimodal therapy would improve outcomes in high-risk neuroblastoma.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom